Category Archives: Parkinson’s Treatment

Introduction In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to a global pandemic of coronavirus disease 2019 (COVID-19). The infectious coronavirus leads to a severe respiratory syndrome and potentially to neurological disorders.1 Older people with comorbidities, including diabetes mellitus, cardiac failure, and respiratory disease, are at increased risk for serious COVID-19 illness. Parkinsons disease (PD) is more prevalent in older people who are often frail and have comorbidities; therefore, elderly patients with PD could be at risk of severe COVID-19 disease.1,2 Many countries implemented lockdowns and social distancing to control the COVID-19 pandemic. Continue reading →

Matt Baron/BEI/Shutterstock After nearly 35 years of marriage,Michael J. Continue reading →

The three keynote speakers are: UTSA President Taylor Eighmy will provide remarks today. This discussion could also inspire novel research directions and foster collaboration among researchers from worldwide, added Zhu, who is serving as the events general co-chair. Five conferences will be held during CPS-IoT Week, including the 26th ACM International Conference on Hybrid Systems: Computation and Control and the ACM/IEEE International Conference on Internet of Things Design and Implementation Continue reading →

Rigshospitalet, Aarhus University, and T&W Engineering collaborate on a groundbreaking project to develop an ear-EEG device for early detection of Alzheimers and Parkinsons diseases. Funded by a DKK 15 million grant from Innovation Fund Denmark, the device measures brains electrical activity and sleep patterns, which can indicate early signs of these neurodegenerative disorders Continue reading →

Regardless of how much you hate sweating, not sweating at all can be an indication of a health condition. Here's what lack of sweat mean and what you can do to tackle it. Sweating, also known as perspiration, is the release of a salt-based fluid from sweat glands, which helps regulate body temperature Continue reading →

LONDONandNEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2023, and provided a corporate update. We are off to a strong start this year with progress across multiple clinical-stage programs and a growing body of data supporting our proprietary gene regulation technology, said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. Continue reading →

RESEARCH TRIANGLE PARK, N.C., May 11, 2023 /PRNewswire/ --Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 11 presentations offering insights into the research and development of adeno-associated virus (AAV) therapies for a range of diseases at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 1620, 2023, in Los Angeles, USA. Continue reading →

We explore how organisations around the world marked World Parkinsons Day this year and why improved awareness and recognition of the event are crucial for those in the community Many people are unaware that World Parkinsons Day is still not officially recognised as a global health day, says Veronica Clark, president of Parkinsons Europe. Every year on 11 April, World Parkinsons Day invites people from around the world to unite to raise awareness of the condition and to celebrate the work being done in the community Continue reading →

Researchers are using a pioneering "Benjamin Button" reverse ageing technique to come to a better understanding of Parkinson's, which could lead to more effective treatments. The technique takes skin cells that have been donated by people with the condition and turns them back into stem cells by using a combination of "reprogramming factors". Stem cells have the potential to become almost any other cell in the body, making them a useful tool to study conditions such as Parkinsons, as they can make studying the brain more accessible Continue reading →

SAN DIEGO, May 12, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new analyses of Phase 2 data of the investigational drug crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) and post hoc analyses of Phase 3 data for EFMODY (hydrocortisone modified-release hard capsules). EFMODY is approved by the European Commission for the European Economic Area (including Northern Ireland) (EEA) and by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of adults and adolescents (12 years and older) with CAH. Continue reading →